295 related articles for article (PubMed ID: 25341011)
1. Recent therapeutic advances in the treatment of colorectal cancer.
Ciombor KK; Wu C; Goldberg RM
Annu Rev Med; 2015; 66():83-95. PubMed ID: 25341011
[TBL] [Abstract][Full Text] [Related]
2. EGFR and downstream genetic alterations in KRAS/BRAF and PI3K/AKT pathways in colorectal cancer: implications for targeted therapy.
Berg M; Soreide K
Discov Med; 2012 Sep; 14(76):207-14. PubMed ID: 23021375
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy of metastatic colorectal cancer.
Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
[TBL] [Abstract][Full Text] [Related]
4. The role of the PI3K pathway in colorectal cancer.
Papadatos-Pastos D; Rabbie R; Ross P; Sarker D
Crit Rev Oncol Hematol; 2015 Apr; 94(1):18-30. PubMed ID: 25591826
[TBL] [Abstract][Full Text] [Related]
5. From tumour heterogeneity to advances in precision treatment of colorectal cancer.
Punt CJ; Koopman M; Vermeulen L
Nat Rev Clin Oncol; 2017 Apr; 14(4):235-246. PubMed ID: 27922044
[TBL] [Abstract][Full Text] [Related]
6. Systemic treatment for metastatic colorectal cancer in the era of precision medicine.
Sandhu J; Lavingia V; Fakih M
J Surg Oncol; 2019 Apr; 119(5):564-582. PubMed ID: 30802315
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in personalized colorectal cancer research.
Kraus S; Nabiochtchikov I; Shapira S; Arber N
Cancer Lett; 2014 May; 347(1):15-21. PubMed ID: 24491406
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.
Migliardi G; Sassi F; Torti D; Galimi F; Zanella ER; Buscarino M; Ribero D; Muratore A; Massucco P; Pisacane A; Risio M; Capussotti L; Marsoni S; Di Nicolantonio F; Bardelli A; Comoglio PM; Trusolino L; Bertotti A
Clin Cancer Res; 2012 May; 18(9):2515-25. PubMed ID: 22392911
[TBL] [Abstract][Full Text] [Related]
9. MODUL-a multicenter randomized clinical trial of biomarker-driven maintenance therapy following first-line standard induction treatment of metastatic colorectal cancer: an adaptable signal-seeking approach.
Schmoll HJ; Arnold D; de Gramont A; Ducreux M; Grothey A; O'Dwyer PJ; Van Cutsem E; Hermann F; Bosanac I; Bendahmane B; Mancao C; Tabernero J
J Cancer Res Clin Oncol; 2018 Jun; 144(6):1197-1204. PubMed ID: 29644408
[TBL] [Abstract][Full Text] [Related]
10. Molecular Targeted Drugs and Treatment of Colorectal Cancer: Recent Progress and Future Perspectives.
Geng F; Wang Z; Yin H; Yu J; Cao B
Cancer Biother Radiopharm; 2017 Jun; 32(5):149-160. PubMed ID: 28622036
[TBL] [Abstract][Full Text] [Related]
11. Targeted therapy for colorectal cancer metastases: A review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer.
Piawah S; Venook AP
Cancer; 2019 Dec; 125(23):4139-4147. PubMed ID: 31433498
[TBL] [Abstract][Full Text] [Related]
12. Precision Medicine in Metastatic Colorectal Cancer: Relevant Carcinogenic Pathways and Targets-PART 2: Approaches Beyond First-Line Therapy, and Novel Biologic Agents Under Investigation.
Weinberg BA; Hartley ML; Salem ME
Oncology (Williston Park); 2017 Jul; 31(7):573-80. PubMed ID: 28712102
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic Targeting of the Tumour Microenvironment in Metastatic Colorectal Cancer.
Dmello RS; To SQ; Chand AL
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669775
[TBL] [Abstract][Full Text] [Related]
14. Biology and genetics of colorectal cancer.
Walker J; Quirke P
Eur J Cancer; 2001 Oct; 37 Suppl 7():S163-72. PubMed ID: 11887987
[No Abstract] [Full Text] [Related]
15. Current evidence and controversies in the incorporation of biologics for metastatic colorectal cancer.
Ciombor KK; Goldberg RM
Hepat Oncol; 2014 Jun; 1(3):331-345. PubMed ID: 30190967
[TBL] [Abstract][Full Text] [Related]
16. Clinical Trials and Progress in Metastatic Colon Cancer.
Mody K; Bekaii-Saab T
Surg Oncol Clin N Am; 2018 Apr; 27(2):349-365. PubMed ID: 29496094
[TBL] [Abstract][Full Text] [Related]
17. High-Throughput Screening of Combinatorial Immunotherapies with Patient-Specific
Kather JN; Charoentong P; Suarez-Carmona M; Herpel E; Klupp F; Ulrich A; Schneider M; Zoernig I; Luedde T; Jaeger D; Poleszczuk J; Halama N
Cancer Res; 2018 Sep; 78(17):5155-5163. PubMed ID: 29967263
[TBL] [Abstract][Full Text] [Related]
18. [Recent progress in research of colorectal cancer].
Inoue M
Nihon Shokakibyo Gakkai Zasshi; 2012 Dec; 109(12):2007-13. PubMed ID: 23221048
[No Abstract] [Full Text] [Related]
19. Precision medicine for metastatic colorectal cancer in clinical practice.
Riedesser JE; Ebert MP; Betge J
Ther Adv Med Oncol; 2022; 14():17588359211072703. PubMed ID: 35237350
[TBL] [Abstract][Full Text] [Related]
20. Metastatic Colorectal Cancer: Lessons Learned, Future Possibilities.
Venook AP
J Natl Compr Canc Netw; 2016 May; 14(5 Suppl):666-8. PubMed ID: 27226509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
